AbbVie stock draws a Moderate Buy consensus from 31 brokers

Published on 09/29/2026 at 12:30 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

AbbVie stock was trading at EUR 234.80 on September 29, 2026, plus 0.41 percent versus EUR 233.85. Q2 revenue reached USD 16.99 billion, up 10.20 percent year over year.

Fotorealistisches Pharma-Forschungslabor mit Petrischalen und Wissenschaftlern in Schutzkleidung — AbbVie Inc. US00287Y1091 fotorealistisches Pharma Forschungslabor mit Petrischalen Wissenschaftlern Immunologie Onkologie Biopharma, Illustration mit AI erstellt.

AbbVie Inc. stock (ISIN US00287Y1091) was trading at EUR 234.80 at Lang & Schwarz on September 29, 2026, up 0.41 percent from the prior close of EUR 233.85. The latest market view gives the drugmaker a Moderate Buy consensus from 31 brokerages and an average one-year target of USD 272.66, according to MarketBeat on September 29, 2026.

Revenue growth supports the view

AbbVie reported USD 16.99 billion in second-quarter 2026 revenue, up 10.20 percent from the same quarter a year earlier. Adjusted EPS came in at USD 3.65, beating the USD 3.61 consensus by USD 0.04, while the company set Q3 adjusted EPS guidance at USD 3.84-3.88, MarketBeat reported.

The comparison matters because the latest quarter combined double-digit revenue growth with a measurable earnings beat. AbbVie also reported second-quarter GAAP diluted EPS of USD 2.03, while adjusted operating margin reached 48.30 percent, according to StockTitan.

Guidance sets the next test

AbbVie reaffirmed full-year 2026 adjusted EPS guidance of USD 13.87-14.07 and Q3 guidance of USD 3.84-3.88. The full-year midpoint of USD 13.97 sits below the USD 14.02 consensus cited in the September 3 guidance update, creating a clear benchmark for the next report.

The Apogee acquisition adds a counterweight to the growth story: AbbVie expects the transaction to reduce adjusted diluted EPS by USD 0.14 in 2026. The filing summary also says the company expects the deal to become accretive in 2032, making near-term dilution a measurable trade-off for pipeline expansion, StockTitan reported.

Stock remains near its yearly high

AbbVie has a 52-week range of USD 190.75 to USD 269.39 and a market capitalization of USD 470.7 billion as of September 28, 2026. The current euro quote therefore sits alongside a US-listed share price that remains within 1.86 percent of its 52-week high, based on the same dated market figures.

The next earnings report is scheduled for October 23, 2026, for Q3 2026, according to TradingView. For investors, the key checkpoint is whether the USD 3.84-3.88 quarterly guidance range can keep pace with the stock's elevated position near its yearly high.

AbbVie stock and its current quote

AbbVie stock was trading at EUR 234.80 at Lang & Schwarz on September 29, 2026 at 12:25 p.m. CEST, plus 0.41 percent versus the prior close of EUR 233.85 at Lang & Schwarz on September 28, 2026.